Improvement of Interstitial Cystitis Symptoms and Problems That Developed During Treatment With Oral Ipd-1151t

Ueda, Tomohiro; Tamaki, Masahiro; Ogawa, Osamu; Yamauchi, Tamio; Yoshimura, Naoki

doi:10.1097/00005392-200012000-00011

Cited by 14 publications

(26 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of suplatast tosilate was reported for the first time by Ueda. 8 The efficacy of steroids, however, was doubted early in both Europe and America, and is no longer widely used for the initial treatment because neither the appropriate dosage nor administration period has been established.…”

Section: Discussionmentioning

confidence: 99%

Recent trends in patient characteristics and therapeutic choices for interstitial cystitis: Analysis of 282 Japanese patients

et al. 2007

Self Cite

View full text Add to dashboard Cite

Objectives:We investigated the characteristics of recent male and female patients diagnosed with interstitial cystitis (IC), then investigated which therapy was chosen by the attending urologist. Methods: Materials were 282 IC patients diagnosed and treated during the past 3 years (sampling from Japanese IC database). Gender, age, medical history and predominant symptoms were investigated. In addition, we investigated the interval before a diagnosis was established. In laboratory findings, we investigated voided volume, urinalysis findings and cystoscopic findings. Regarding therapy, we investigated which therapy was chosen as the first line. Results: The gender ratio was about 1.0:5.6 (male : female). Regarding age distribution, patients in their 60s were the most frequent (65 cases, 31.3%). The interval before diagnosis of IC was 36.5 months on average (1-360 months). Regarding medical history, intrapelvic surgery was the most common and repeated urinary tract infection was next. The most frequent symptom was urinary frequency (295 cases, 98.3%). Urinary urgency was noted in 186 cases (62%) and supra-pubic pain was noted in 125 cases (41.6%). The once voided volume was 104.3 mL on average (50-200 mL). The most common cystoscopic finding was glomerulation (158 cases). Ulcer was present in only 19 cases. The most widely carried out therapy was hydrodistension (208 cases, 67.9%). Oral suplatast tosilate (197 cases, 65.6%), antihistamine (77 cases, 25.6%) and intravesical dimethylsulfoxide (69 cases, 23%) followed. Conclusions: Regarding characteristics, the age distribution was older than other countries. The most frequent symptom was urinary frequency. Oral suplatast tosilate was one of the popular therapies in Japan.

show abstract

Section: Discussionmentioning

confidence: 99%

Recent trends in patient characteristics and therapeutic choices for interstitial cystitis: Analysis of 282 Japanese patients

et al. 2007

Self Cite

View full text Add to dashboard Cite

show abstract

“…Good symptom response is recorded after 1 year of treatment, and no significant side effects were reported. 72 Quercetin This bioflavinoid has shown limited but promising results in BPS. An oral drug combining quercetin, chrondroitin sulphate and sodium hyaluronate significantly improved symptoms in treatment-refractory patients (6 capsules per day for 6 months).…”

Section: Suplatast Tosilate (Ipd-1151t)mentioning

confidence: 99%

Bladder pain syndrome: contemporary management and future strategies

Biers

Thiruchelvam

2013

Journal of Clinical Urology

View full text Add to dashboard Cite

Several studies have formulated body maps to document co-existing pain problems in BPS. Pain outside of the bladder region is found in 73% of cases. 8 Pain in the vagina, pelvis, lower back, lower abdomen or buttocks is found in 27%. 8 Patients commonly report dyspareunia and pain which fluctuates with the menstrual cycle. 6 BPS type 3C patients describe their pain as sharp, stabbing and hot burning, suggesting pain specifically from their ulcer, whereas non-ulcer BPS patients describe it as aching, cramping and tender, 6 perhaps describing their more generalised pain.

show abstract

“…A report from Japan suggested increase in bladder volume and symptomatic improvement in a majority of patients without serious side effects. 133 (level V) No significant adverse event is known.…”

Section: Suplatast Tosilatementioning

confidence: 99%

Japanese guideline for diagnosis and treatment of interstitial cystitis

et al. 2008

Self Cite

View full text Add to dashboard Cite

Interstitial cystitis (IC) is a disease of the urinary bladder with lower urinary tract symptoms such as urinary frequency, bladder hypersensitivity and/or bladder pain and resultant serious impairment of quality of life. In Japan, assuming that IC is very rare, research activity and medical care of IC have been sparse until 2001, when the Society of Interstitial Cystitis of Japan (SICJ) and a patient support group were founded.

show abstract

Improvement of Interstitial Cystitis Symptoms and Problems That Developed During Treatment With Oral Ipd-1151t

Abstract: Our study suggests that immunological responses are involved in the development of interstitial cystitis symptoms. IPD-1151T could be a new oral agent for treatment of voiding symptoms and bladder pain in patients with interstitial cystitis.

Cited by 14 publications

References 20 publications

Recent trends in patient characteristics and therapeutic choices for interstitial cystitis: Analysis of 282 Japanese patients

Recent trends in patient characteristics and therapeutic choices for interstitial cystitis: Analysis of 282 Japanese patients

Bladder pain syndrome: contemporary management and future strategies

Japanese guideline for diagnosis and treatment of interstitial cystitis

Contact Info

Product

Resources

About